basic ep excud amorit one-tim item pro
last friday approv zolgensma piqray well insight
manag meet rais nv ep estim year nv
remain top pick key excit new product prospect
friday issu extens note detail mani highlight last week
analyst event highlight togeth higher number zolgensma
piqray breast cancer fevipipr asthma led higher nv ep estim
 chang includ higher margin assumpt clear messag top
manag slightli higher tax rate post swiss tax reform elimin
us derm/or solid sale sandoz revenu begin prior model
alreadi reflect extract alcon
reflect chang note rais nv ep estim
chang ep compound-annual-growth-rate higher sale estim zolgensma
forecast remain intact year piqray fevipipr
off-set divestitur sandoz us derm/or solid sale modest
reduct sale made year sale compound-annual-growth-rate also remain intact
zolgensma approv treatment pediatr patient less year old
spinal muscular atrophi sma bi-allel mutat gene zolgensma
provid function copi human smn gene halt diseas progress
sustain smn protein express one-tim iv infus label allow use sma
type well babi pre-symptomat long less
year age safeti languag expect price
expect paid year equal instal via outcomes-bas contract
although revenu recogn front state
establish newborn screen expect grow next
month forecast zolgensma sale
nv pay royalti sale
piqray alpelisib approv combin use endocrin therapi fulvestr
treat postmenopaus women men advanc
metastat breast cancer follow progress endocrine-bas regimen nv
bullish expect piqray kol lean cautious believ use
second line therapi inhibitor endocrin therapi
er posit breast cancer mutat although nv admit initi use
like inhibitor kol note displac afinitor set
lead guidelin adopt widespread genom test er posit
breast cancer forecast piqray sale
vs previous
pleas see page report import disclosur
nv strength outweigh challeng strength includ entresto cosentyx outlook
new product posit roll-out notabl zolgensma willing consid
value-cr action potenti sandoz share repurchas challeng includ
roll-out kymriah kisqali increas competit cosentyx sandoz struggl
io strategi may may differenti sale ep growth prospect
appear averag believ opportun upward revis time
entresto heart failur cosentyx
zolgensma sma crizanlizumab
sickl cell regulatori progress
aimovig lutathera uptak
kymriah kisqali uptak eu
entresto cosentyx zolgensma
brolucizumab success greater
entresto cosentyx zolgensma
brolucizumab meet expect
sandoz continu struggl
novarti global biopharmaceut compani compani two segment
pharmaceut sandoz includ gener pharmaceut biosimilar
compani data cowen compani estim
gross non-op report netp inc tax rateincomeshar mm chg mm mm mm mm mm mm epschg transfer ophtha over-the-counter product pharma alcon effect oper incpretax incom dsg asal total cowen
compani data cowen compani estim
fgn fgn diovan fgn diovan fgn diovan/co-diovan exforg fgn exforg fgn exforg lotrel- matur total cowen
compani data cowen compani estim
glivec fgn fgn gleevec/glivec tasigna tasigna fgn fgn tasigna afinitor/votubia afinitor/votubia fgn fgn afinitor/votubia votrient/patorma votrient/patorma fgn votrient/patorma fgn sandostatin sandostatin fgn fgn sandostatin franchis cowen
compani data cowen compani estim
 cont promacta/revolad promacta/revolad fgn promacta/revolad fgn exjade/jadenu exjade/jadenu fgn fgn exjade/jadenu tykerb tykerb fgn tykerb fgn arzerra arzerra fgn arzerra fgn kymriah cowen
compani data cowen compani estim
 hycamtin hycamtin fgn hycamtin fgn zometa fgn zometa fgn zometa femara fgn fgn femara total cowen
compani data cowen compani estim
gilenya gilenya fgn lc gilenya fgn fx gilenya total zolgensma mayzent aimovig extavia tegretol cr/xr ofatumumab trilept exelon/patch exelon/patch fgn lc exelon/patch fgn fx exelon/patch total comtan group comtan group fgn lc comtan group fgn fx comtan group total ritalin group ritalin group fgn lc ritalin group fgn fx ritalin group total neurosci matur neurosci total neurosci cowen
compani data cowen compani estim
xolair ultibro fevipipr seebri onbrez/arcapta tip tobi respiratori matur respiratori total respiratori dermatolog cosentyx cosentyx fgn lc cosentyx fgn fx cosentyx myfort myfort fgn lc myfort fgn fx myfort total neoral/sandimmun neoral/sandimmun fgn lc neoral/sandimmun fgn fx neoral/sandimmun total ilari certican/zortress cubicin cowen
compani data cowen compani estim
osilodrostat ligalizumab other iid matur iid total immunolog dermatolog product voltaren/cataflam everolimu stent manf enablex/emselex product matur ogu total brolucizumab lucenti fgn lc lucenti fgn fx lucenti travoprost travoprost fgn lc travoprost fgn fx travoprost total topic olopatadin topic olopatadin fgn lc topic olopatadin fgn fx topic olopatadin total xiidra luxturna total innov medicin sale dermatolog cont cowen
compani data cowen compani estim
cowen compani
market entresto fgn lc entresto fgn market eu hypertens hf inhib piii hfpef nda post acut mi nda potentialgalvu inhibitor launch ex-u distribut stop germani nmnm-secondari prevent cv event elev lipid file nmnm-iga nephropathi membran nephropathi glomerulopathi file gener plain form hctz combo launcheddiovan fgn lc diovan fgn exp spain portug brazil eu japan sale patent expir stoppag altitud safeti substanti tarnish prospectsexforg -declin due gener competitionexforg fgn lc exforg fgn -eu data exclus exp litig marketsexforg exforg hct exclus exp xl sale sale ex-u simvastatin gener erod sharelotrel- nmnm-share exclus teva at-risk launch end patent expir patent compoundstot cowen
cowen compani
gist sun launch gener indic gist teva apotex also launchedglivec fgn lc glivec fgn incid greater ex-u gener launchedgleevec/glivec patent expir treatment-fre remiss approv fgn lc tasigna fgn line cml gist studi discontinuedafinitor/votubia competit pressur limit gener expect end fgn lc afinitor/votubia fgn expir januari pedi exclus afinitor/votubia mrcc sega net aml brca gl/lung approv seizur approv eu votrient/patorma rcc advanc soft tissu sarcoma pressur io votrient/patorma fgn lc votrient/patorma fgn rcc advanc soft tissu sarcoma pressur io vegr tyrosin kinas inhibitor approv rcc incyt market ou myelofibrosi myeloprolif polycythemia vera gvhd acute/chron net pressur lutathera net pursu earlier settingssandostatin fgn lc sandostatin fgn franchis formul patent exp impact sale two-third ex inhibitor line breast cancer approv us eu ekg requir solid tumor longer develop braf inhibitor metastat adjuv melanoma approv mono combo us mutat mono eu combo approv lung cancer mek inhibitor metastat adjuv melanoma approv mono us/eu mutat combo approv lung cancer cowen
cowen compani
 cont promacta/revolad itp anemia assoc hcv tx review sever aplast anemia promacta/revolad fgn lc promacta/revolad fgn itp anemia assoc hcv tx treatment low platelet count fda approv restrict label md aml phase inject gen sandostatin approv cush resist carcinoid acromegali approv eu net oral phase oral competit delay exjade/jadenu expir fgn lc exjade/jadenu fgn expir tablet iron overload label expans myelosdysplast syndrom includ new formul tykerb mbc fail adjuv tykerb fgn lc tykerb fgn mbc arzerra approv refractori first line cll relaps approv inhl refractori file arzerra fgn lc arzerra fgn approv refractori move compassion use fulli human mab right remain indicaton acquir gep-net indic develop via advanc acceler acquisit close target cell immunotherapi approv pedi aug dlbcl may r/r fl r/r dlbcl file cll file signal transduct inhibitor aggress system mastocytosi aml approv nmnm-mcrpc file endpoint via endocyt acqusit close nmnm-alpelisib alpha inhib line advanc postmenopaus bc trial posit approv us tnbc met exon nsclc nda egfrm file nmnm-net taf/mek mbraf melanoma file metastat melanoma file sickl cell diseas file advanc nsclc approv first therapi crizotinib nave approv tough competit oral deacetylas inhibitor relaps multipl myeloma approv eu cowen
cowen compani
 nmnm-cml file file nmnm-crc rcc file nmnm-acut myeloid leukemia file hycamtin hycamtin fgn lc hycamtin fgn topotecan refractori sclc first line ovarianzometa fgn lc zometa fgn patent expir nmnmfemara fgn lc femara fgn inhibitor exp gener june eu gener may gsk oncolog acquisit close cowen
cowen compani
gilenya exp includ pedi assum litig extend exclus gilenya fgn lc gilenya fgn fx patent expir japan patent expir gilenya total pedi ms apprv fail ppm zolgensma sma approv file eu approv via avexi acq cash close file type rett syndrom mayzent nmnm-siponimod modul oral approv us/eu broad ms label cv monitor pt aimovig nmnm-erenumab select cgrp ra migrain sq approv episod chronic migrain co-promot right row ex japan extavia ms/ betaseron agreement bayer launch tegretol cr/xr patent patient unlik switch ofatumumab mab relaps multipl sclerosi sq phase ii file mab alzheim diseas im phase ii file inhibitor alzheim diseas oral phase ii file trilept composit patent expir gener launch exelon/patch launch sdz launch author exelon/patch fgn lc exelon/patch fgn fx exelon/patch total drive growth franchis aricept gener clip oral sale comtan group comtan group fgn lc comtan group fgn fx comtan group total stalevo pd orion stalevo paragraph iv file teva sun comtan exp ritalin group ritalin group fgn lc ritalin group fgn fx ritalin group total ritalin la focalin xr focalin exclus expir patent exp neurosci matur neurosci clozariltot neurosci cowen
cowen compani
xolair asthma roch chronic spontan urticaria nasal polyp file ultibro fdc indacaterol/glycopyrronium bromid copd launch germani netherland japan right licens sunovion bid dose fevipipr antagonist phase asthma data file seebri qd lama glycopyrronium copd approv japan right licens sunovion bid dose onbrez/arcapta laba indacaterol copd approv right licens sunovion nmnm-laba/steroid combin indacaterol/mometason asthma file ex-u nmnm-laba/ics/lama tripl combin indacaterol/mometasone/glycopyrronium asthma file nmnm-sever asthma file nmnm-copd file tip sold global right total deal tobi nmnm-inhal tobramycin cystic fbrosi replac tip gener respiratori matur respiratori respiratori dermatolog cosentyx share competit increas cosentyx fgn lc cosentyx fgn fx eu japan cosentyx psoriasi psoriat arthriti ankylos spondyl non-radiograph hs vs humira myfort myfort fgn lc myfort fgn fx myfort total transplant agent neoral/sandimmun neoral/sandimmun fgn lc neoral/sandimmun fgn fx neoral/sandimmun total row major sale gener substitut minim ilari anti-il beta mab cap approv refractori gout bla cr approv sjia /eu approv period fever syndrom approv eu nsclc adjuv loe us eu certican/zortress approv us kidney/liv approv eu kidney/liver/heart cubicin mrsa antiifect european right cowen
compani data cowen compani estim
osilodrostat aldosteron synthas inhib cush oral file us eu ligalizumab anti-ig mab chronic spontaneous/idiopath urticaria file nmnm-atop dermat file nmnm-atop dermat file nmnm-nash file nmnm-anti-baff primari sjoegren syndrom autoimmun hepat file nmnm-chronic spontan urticaria file other iid basiliximab transplant tyzeka hbv matur iid immunolog product voltaren/cataflam nsaid still grow ex-u everolimu stent manf abbott muscular atrophi file organ transplant sjorgen syndrom file agonist non-alcohol steatohepat nash phase ii file collabor enablex/emselex bladder right sold warner chilcott product matur ogu total brolucizumab antivegf ab fragment neovascular file dme rvo hawk/harri data solid lucenti fgn lc dme cnv brvo crvo lucenti fgn fx lucenti right pat exp off-label avastin use small eylea competit challeng travoprost travoprost fgn lc travoprost fgn fx travoprost total glaucoma topic olopatadin topic olopatadin fgn lc topic olopatadin fgn fx topic olopatadin total antihistamin xiidra nmnm-dri eye acquir takeda mileston close luxturna nmnm-rare inherit retina diseas one-tim gene therapi approv eu spark nmnm-presbyopia file nmnm-dri eye file nmnm-ocular surfac pain file sale alcon restated-tot sale alcon restatedtot competit growth driver innov medicin sale dermatolog cont cowen
compani data cowen compani estim
sale oral solids/derm sold aurobindo close biosimilar approv rituxan longer pursuedrow -lc -includ falcon gener ophthalm biosimilar approvedrow incld biolog binocrit epo airflus gener novarti sale guidanc top line growth year cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl gleevec tasigna
galvu gilenya afinitor lucenti success pipelin product success deal
patent litig patent expir pressur notabl gleevec
manufactur issu challeng non-pharma segment
